PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER THIS POSITIVE DECISION FROM THE USA PATENT OFFICE STRENGTHENS THE COMPANY’S INTELLECTUAL PROPERTY POSITION IN THIS INDICATION UNTIL 2042, ADDING TO THE COVERAGE ALREADY GRANTED IN EUROPE Paris, January 29, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announced that the United States Patent and Trademark Office (USPTO) issued a Noti ...

Financial and Corporate Situation - AB Science reported a reduced operating deficit of €2.7 million for the first half of 2025, a decrease of 24% compared to €3.6 million in the same period of 2024 [4][3] - The company raised €6.3 million through private placements to support ongoing activities, particularly the clinical development of the AB8939 program [25] - The net loss for the first half of 2025 was €5.2 million, an increase of 15.8% from a loss of €4.5 million in the first half of 2024 [6][7] Clinical Development - AB Science received authorization from several European countries for a Phase 3 confirmatory study with masitinib in amyotrophic lateral sclerosis (ALS) [8] - The FDA and EMA approved a Phase 3 confirmatory study with masitinib in metastatic hormone-resistant prostate cancer [13] - New data indicated the efficacy of masitinib in treating Alzheimer's disease, showing improvements in cognitive and behavioral symptoms in a mouse model [15][16] - The AB8939 molecule received orphan drug designation from the EMA for the treatment of acute myeloid leukemia (AML) [21] - A Canadian patent was granted for AB8939, providing protection until 2036 [23] Financial Results Summary - Operating income was €515 thousand, down from €560 thousand in the first half of 2024, attributed to a temporary decline in sales of veterinary medicine [5][7] - Operating expenses decreased by 21.7%, with administrative expenses down by 31.1% [5] - Financial income for the first half of 2025 was €212 thousand, while financial expenses amounted to €2.7 million [7]

Core Points - AB Science has announced the issuance of a Canadian patent for AB8939, which protects its composition and use in treating acute myeloid leukemia (AML) until 2036 [1] - The patent completes the intellectual property coverage for AB8939 across all key geographic areas, including Europe, USA, China, Japan, South Korea, India, Israel, Latin America, and Australia [2] - AB8939 is a novel microtubule destabilizer currently in early phase clinical trials for AML, with the first phase focusing on determining the maximum tolerated dose [3] - The drug is also eligible for regulatory data protection in Canada, preventing generic competition for 8 years post-approval, and has received orphan drug designation from EMA and FDA, providing additional market exclusivity [4] - A separate patent application has been filed to protect AB8939 for treating AML with specific chromosomal abnormalities, potentially extending protection until 2044 [5] - AB8939 targets cancer cells by destabilizing microtubules and inhibiting enzymes essential for cancer stem cell survival [6] - AB Science specializes in developing protein kinase inhibitors for diseases with high unmet medical needs and has a portfolio of molecules including masitinib [7][8]

Core Points - The European Medicine Agency (EMA) has approved the extension of the shelf-life of AB Science's veterinary medicine MASIVET® from 36 months to 48 months [1] - MASIVET® is approved for treating non-resectable dog mast cell tumors (Grade 2 or 3) with confirmed mutated c-kit tyrosine kinase receptor and is available in all EU countries [2] - The shelf-life extension provides flexibility for patients, caregivers, and AB Science in managing inventory levels, reducing the risk of product expiration, and ensuring continuity of therapies [3] Company Overview - AB Science, founded in 2001, specializes in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [4] - The company's lead compound, masitinib, is registered for veterinary medicine and is also being developed for human medicine in various fields including oncology and neurological diseases [5]

Company Announcement - AB Science SA has postponed the publication of its 2024 annual financial report from April 30, 2025, to May 9, 2025, to allow auditors to complete their work [1][2] Company Overview - AB Science, founded in 2001, is a pharmaceutical company focused on the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [3] - The company's lead compound, masitinib, is registered for veterinary medicine and is being developed for human medicine in areas such as oncology, neurological diseases, inflammatory diseases, and viral diseases [4] Additional Information - AB Science is headquartered in Paris, France, and is listed on Euronext Paris under the ticker AB [4] - Further information can be found on the company's website [5]